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Interferon  (IFN) is a pleiotropic protein secreted by
immune cells. IFN signals through the IFN receptor, a pro-
tein complex that mediates downstream signaling events. Stud-
ies into IFN signaling have provided insight into the general
concepts of receptor signaling, receptor internalization, regula-
tion of distinct signaling pathways, and transcriptional regula-
tion. Although IFN is the central mediator of the adaptive
immune response to pathogens, it has been shown to be involved
in several non-infectious physiological processes. This review
will provide an introduction into IFN signaling biology and the
functional roles of IFN in the autoimmune response.
According to the National Institutes of Health, autoimmune
diseases (ADs)3 are one of the top 10 leading causes of death in
female children and women in all age groups up to 64 years of
age (1). Excess secretion of IFNs has been associated with devel-
opment of human ADs (2). Interferons (IFNs) comprise a family
of proteins classified as type I (IFN-, -, -, -, and -), type II
(IFN-, herein IFN), and type III (IFN-1– 4) that have pleio-
tropic roles in immunity, cancer biology, and autoimmunity (2).
Here, we aim to provide a basic understanding of the functions
of the type II IFN and the IFN-signaling pathway (hereafter
referred to as IFN signaling) in a contextual and timing perspec-
tive related to the autoimmune environment and the develop-
ment of ADs.
Biological role of IFN on inflammation
Since Wheelock (3) reported that IFN inhibited viral re-
plication, IFN has become an essential regulator of several
immune processes, including vaccine-mediated responses and
pro-inflammatory CD4 T helper 1 (Th1) cell responses (4). As
an effector cytokine of Th1 immunity, IFN is the key regulator
of macrophage activation via the Janus kinase (JAK)/signal
transducer and activators of transcription (STAT) pathway
(Fig. 1A) (5). Normally, in the early phases of the host immune
response, production of IFN by natural killer cells, CD4T
helper 1 (Th1) cells, and CD8 T cells aims to improve antigen
recognition in antigen-presenting cells (APCs) such as macro-
phages and dendritic cells. IFN activates macrophages toward
the “M1” phenotype, which is characterized by the expression
of high levels of pro-inflammatory cytokines such as Il-1,
IL-12, IL-23, and TNF-; high production of reactive nitrogen
and oxygen intermediates; promotion of Th1 T cell response;
and strong inflammatory activity (6). APCs express major his-
tocompatibility complex (MHC) class I and II proteins and acti-
vate cross-presentation antigenic pathways. In parallel, IFN
signaling generates other cytokines and inflammatory factors to
sustain inflammation, maintain Th1 responses, and inhibit dif-
ferentiation of regulatory T cells, CD4 T helper 2 cells (Th2),
and Th17 cells (7). Despite these amplification steps, IFN sig-
naling is generally short-lived to elicit functional recovery of
homeostasis, including tissue repair and reestablishment of tis-
sue physiology.
IFN signaling: Canonical and non-canonical pathways
In the context of inflammation, IFN induces a rapid
response via the JAK/STAT or canonical pathway. However, in
the context of ADs, maintenance of chronically high levels of
IFNs leads to activation of both canonical and non-canonical
pathways, albeit in a cell- and context-specific manner.
Canonical IFN-signaling pathways
In the canonical pathway of IFN signaling, IFN dimerizes
and binds to the two IFNGR1 receptors. The IFNGR is com-
posed of two distinct chains, the high affinity IFNGR1 () and a
low affinity IFNGR2 () (8). The identification of a glycosyla-
tion-deficient mutant residue in the IFNGR1 detailed two key
steps preceding initiation of IFN signaling (9). In the first step,
IFN binding induces the receptors to undergo a conforma-
tional change in lipid nano-domains, whereby the box 1
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domains on the IFNGRs are brought into proximity of each
other allowing recruitment of two JAKs, JAK1 and JAK2, to the
IFNGR1 and IFNGR2 chains, respectively. This recruitment
step occurs independently of their enzymatic activities. In the
second step, JAK1/2 activation induces a second conforma-
tional change that allows STAT1 to associate with the IFN–
IFNGR complex. In turn, JAK1 and JAK2 phosphorylate the
transcription factor STAT1 (pSTAT1) forming a homodimer
that translocates to the nucleus (9). At this moment, the
released IFNGRs associated with the cortical-actin network
and prepared for alternative regulation via receptor trafficking
and endocytosis. Importantly, these events demonstrate that
receptor internalization may not be required for IFN signaling
to take place.
In the nucleus, pSTAT1 binds with high affinity to DNA
sequences termed the -interferon-activated site (GAS) to ini-
tiate transcription of interferon-stimulated genes (ISGs) (Fig.
1A) (11). At the same time, acetylation of pSTAT1 sets the
timer for STAT1 inactivation via complex formation between
acetylated STAT1 and the protein-tyrosine phosphatase T
cell protein-tyrosine phosphatase (TCP45) (12). In turn, his-
tone deacetylase 3 (HDAC3) deacetylates STAT1, thus per-
mitting a new cycle of phosphorylation and re-stimulation
(13). Hence, the rapid increase of pSTAT1 after IFN stim-
ulation elicits a reversible and dynamic response to rapidly
restore homeostasis.
Non-canonical IFN signaling pathways
The observation that IFN is capable of inducing gene
expression in STAT1/ bone marrow-derived macrophages
suggested that IFN can act independently of STAT-1 or in an
alternative non-canonical fashion (14). Generally, the activa-
tion of non-canonical pathways appears to be later rather than
earlier after STAT1 activation. Nevertheless, there is evidence
suggesting that non-canonical pathways could be activated in
the absence or presence of Stat1 in a context-dependent man-
ner. In the absence of STAT1 (Fig. 1B), IFN can activate
STAT3, in a JAK-STAT-dependent process that results in acti-
vation of GAS-regulated genes (15, 16). Moreover, the absence
of Stat1 in primary fibroblasts or neurons led to enhanced ERK
activation following IFN addition, implying that the cell-spe-
cific availability of signal transducers can diversify the cellular
response following IFN engagement (17). STAT-independent
IFN signaling can occur via activation of other MAPKs, such
as PyK2, ERK1/2, and JNK (18, 19); the adaptor proteins CrkL
and small G protein Rap1 (20); and the Src homology 2 domain-
containing protein-tyrosine phosphatases SHP-1 and SHP-2
(18, 21). Note, IFN activation of different kinases such as
ERK1/ERK2 (MAPKs) (22) or glycogen synthase kinase 3
(GSK3) signaling (23) results in activation of different tran-
scription factors. For example, IFN activation of ERK reg-
ulates binding of CCAAT/enhancer-binding protein-
(C/EBP) to a novel IFN response element called GATE (22).
GATE has little homology with GAS and binds to different
transacting factors such as C/EBP. Recent evidence found that
phosphorylation of C/EBP involves IFN-stimulated proteo-
lytic processing of ATF6, and ERK1 and ERK2 are necessary to
control autophagy of several infectious agents (24). Conversely,
IFN activation of GSK3 via the phosphoinositide 3-kinase-
AKT pathway regulates CREB/AP1-dependent DNA binding
to suppress IL-10 production (23).
Conversely, in the presence of Stat1, activation of canonical
and non-canonical pathways could happen simultaneously
(Fig. 1A). However, the outcomes of such activation are cell-
and context-specific. For example, in mice infected with sys-
temic Dengue, Stat1-dependent pathways were required for
early viral control, but Stat1-independent pathways were later
required for viral clearance (25). Furthermore, in a mouse
model of encephalitis, the activation of Stat1-dependent and
Stat1-independent pathways advanced IFN-induced reduc-
tion of myelin sheath thickness in the CNS despite Stat1 knock-
down (26). Apparently, initiation of these alternative signaling
pathways starts at the JAK activation sites in IFNGR1 with
the recruitment of adaptor molecules such as MyD88 adap-
tor-like (Mal) (27) or the Fyn kinase (28). MAL is encoded
by the gene Toll-interleukin 1 receptor domain containing
adaptor protein (TIRAP). Noticeably, Mal-dependent IFNGR
signaling required phosphorylation of the mitogen-activated
protein kinases (MAPK) p38, not Stat1, for phagosome matu-
ration and killing of intracellular infectious organisms such as
Mycobacterium tuberculosis. Moreover, defects in the Mal-de-
pendent IFN-signaling pathway due to non-synonymous sin-
gle nucleotide polymorphism at S180L in the human TIRAP
gene explains best the increased susceptibility of SLE patients
for mycobacterial and pneumococcal infections (27). Similarly,
recruitment of the Src kinase Fyn results in the formation of a
complex that allows IFN to activate Stat5b via PI3K signaling
(29). The ability to activate Stat5 while preserving IFN activa-
tion of STAT1-dependent immune events represents an advan-
tageous adaptation mechanism to regulate macromolecular
permeability in enteric epithelium with low STAT1 levels.
Moreover, IFN activation of AKT and mTOR via PI3K
improved mRNA translation of IFN-regulated genes comple-
Figure 1. Overview of the STAT-1 canonical and non-canonical signaling pathways elicited by IFN. As a dimer, IFN (orange) binds the IFNGR, which is
composed of the IFNGR1 and IFNGR2 subunits, the kinases Jak1/Jak2. A, in canonical IFN signaling, phosphorylation of Jak1 and JAK2 results in the phos-
phorylation of STAT1 (center). A STAT1 homodimer translocates to the nucleus and binds to GAS found in the promoters of IFN-regulated genes such as HLA-A,
NOS-2, IRF1, PDCD1, and CD274. Recruitment of adaptor proteins associated with IFNGR2 such as MAL and Fyn results in non-canonical STAT1 signaling.
MAL-dependent IFN- receptor (IFNGR) signaling elicits signaling via MAPK p38 phosphorylation to up-regulate expression of the chemokine IP-10, antimy-
coplasma proteins, and formation of autophagosomes (left). GSK3 activation and Fyn elicit pSTAT5 recruitment to activate PI3K to regulate cell membrane
permeabilization. Alternatively, IFN activation of GSK3 via PKC	 activates AKT/mTOR regulation of survival responses. Nevertheless, upon STAT activation,
control mechanisms aiming to regulate signaling target either the JAK catalytic sites with SOCS proteins (upper right corner) or blockade of the STAT dimers
binding to GAS sites with PIAS or through binding with un-phosphorylated STAT2. Alternatively, IFN priming increases IRF9, which is recruitment to STAT1
dimers for binding to ISRE sites. Antiviral and antibacterial responses benefit from this mechanism. B, in cells not expressing STAT1, STAT3 can be phosphor-
ylated by Jak1/Jak2 resulting in translocation of the STAT3 dimer to GAS sites. Moreover, IFN activation of ERK results in C/EBP activation and binding to a
novel IFN-response element (GATE). Figure has been adapted and modified from Refs. 17 and 29.
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menting STAT1-dependent mechanisms (30). Thus, IFN can
regulate complex processes beyond their known short-term
effects. Therefore, the overall biological effect of IFN signaling
likely results from a well-adjusted combination of Stat1-depen-
dent and Stat1-independent mechanisms activated sequen-
tially during progression of the inflammatory disease.
Alternative mechanisms regulating the IFN signaling
via endocytosis
As diverse as the IFN signaling downstream pathways could
be, all actions start generally at the IFNGR. As human IFN
does not signal in mouse or rat cells, evidence that microinjec-
tion of human IFN elicited antiviral activity in murine cells
suggested that the IFNGR provides species specific responses
to IFN (31). Further evidence showing that retention of IFN
within cells also resulted in an IFN-dependent signaling
leaded researchers to further claim that the IFNGR drives spe-
cies specificity responses (32, 33). Thus, the IFNGR holds the
key to control the activity of IFN among species (34).
The regulation of IFN signaling involves essential manage-
ment mechanisms that regulate the differential expression and
cell-surface localization of the IFNGR chains (Fig. 2). IFNGR1 is
usually expressed in excess, whereas IFNGR2 is more tightly
regulated in most but not all cell types (35, 36). In fact, the
absence of IFNGR2 on the surface of Th1 cells supports the
model that regulation of its surface expression regulates
responsiveness to IFN (37). Moreover, several viruses such
as the vaccinia virus and myxoma virus encode and secrete
IFN receptor mimetics, which are peptides with significant
sequence similarity to the human and mouse receptors for
IFN, to neutralize IFN activity (38). These data suggest that
cell regulation of IFNGR accounts for cell-specific differences
in response to IFN and how a target cell becomes unrespon-
sive to further IFN stimulation.
Recent data showing that the IFNGR1 and IFNGR2 are
loosely associated in sphingolipid-rich areas on the cell surface,
called lipid micro-domains, provided mechanistic details over
their complex formation (39, 40). As shown in Fig. 2, upon IFN
dimer binding to IFNGR1 and IFNGR2, a ternary complex is
formed within the micro-domains in preparation to deliver
downstream signaling from the cell surface to the nucleus
(41). Note, IFN–IFNGR complex readiness is independent of
receptor internalization (42). Upon Stat1 activation and inter-
nalization, the two IFNGRs are differentially processed within
cells using clathrin-dependent or clathrin-independent mech-
anisms (43). Clathrin-dependent endocytosis utilizes the pro-
tein clathrin to mediate endocytosis and is the primary mecha-
nism by which the IFNGR1 is recycled to the cell surface (42).
Infectious organisms such as herpesvirus K3-5 or Trypanosoma
cruzi down-regulate the surface expression of host IFNGR by
increasing their endocytosis rates, which leads to suppression
of cell-mediated immunity (44, 45). Conversely, clathrin-inde-
pendent endocytosis uses sphingolipid-rich caveolae, also
known as lipid rafts, to regulate IFNGR2 at the cell surface (46).
Human T cells use this pathway to limit sensitivity to IFN as a
strategy for dampening the host immune response (47).
Recently, a novel mechanism explains how membrane cell
dynamics modulates cell-to-cell communication via cytokines
(Fig. 2). Surprisingly, positively charged regions of IFN, IL-12,
and IL-23 were proved to interact directly with negatively
charged cell-surface phosphatidylserines (PS) on tumor cells
(48). The cytokine–PS complexes are endocytosed, possibly via
caveolae-dependent mechanisms, to be slowly recycled back to
the cell surface in an autocrine-like manner. Once released,
cytokines bind their respective receptors. This mechanism
explains how tumor cells manage to extend a response after a
short-lived cytokine exposure.
Figure 2. Endocytic mechanisms regulating IFN signaling via differential expression of the IFNGR. IFNGR1 (green) and IFNGR2 (purple) are associated in
lipid micro-domains on the cell surface. In the presence of IFN dimers (orange), the cytokine receptor complex is redirected to clathrin or caveolae sites at the
cell surface. Once there, IFN either binds the receptor or is recruited to PS-rich domains. Then, the IFNG complexes are endocytosed either through clathrin-
dependent events or clathrin-independent events that involve caveolae-dependent mechanisms. IFN–PS complexes are slowly recycled back to the cell
surface, and IFN is released in an autocrine-like manner (left). In contrast, IFN–IFNGR complexes are endocytosed and broke down before being recycled or
degraded. Noticeably, IFNGR2 is enzymatically cleaved and separated for degradation via proteasomes. Meanwhile, IFNGR1 can be recycled to the cell surface
or targeted for degradation. Alternatively, the IFNG–IFNGR–p-STAT1 complex could remain stable and continue translocating to the nucleus using NLS.
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Another less understood and controversial regulatory mech-
anism proposes that the whole IFN/IFNGR structure translo-
cates to the nuclei and defines species selectiveness (32). Inde-
pendent reports showed that such an event is possible due to a
putative nuclear localization sequence (NLS) contained both in
IFN and the IFNGR structures (49). It has been suggested that
those NLS allows IFN to regulate STAT1 trafficking within
cells (50 –52). As the concept of a nuclear localization step
awaits further verification, its relevance on IFN signaling
remains incomplete. Together, controlling the IFNGR expres-
sion at the cell surface is a straightforward control mechanism
available to all cells to regulate responses to IFN.
Chronic exposure to IFN leads to ADs
In ADs, immune cells are exposed, often simultaneously, to
more than one IFN causing integration of IFN signaling (53).
Recently, it was determined that such exposure could go back
up to 3.0 to 4.5 years before individuals are even diagnosed with
ADs such as SLE (54) or rheumatoid arthritis (RA) (55), respec-
tively. In this type of relapsing-remitting ADs, immune cells are
constitutively and constantly exposed to waves of significantly
“high” (relapse or flare state) or “low” (remission state) levels of
type I and type II IFNs during distinct periods of time (56, 57).
Pre-exposure to low sub-activating concentrations of IFNs sen-
sitizes cells to produce enhanced responses to extracellular
inflammatory stimuli that include IFNs themselves, as well as
other cytokines such as tumor necrosis factor  (TNF) or toll-
like receptor activators (58). This process, known as priming, is
characterized by the intracellular accumulation of STATs.
Contrary to acute inflammation, primed immune cells such as
M1 macrophages are the predominant phenotype at sites of
inflammation for ADs such as RA, multiple sclerosis, and lupus
nephritis (59, 60).
IFN priming elicits post-transcriptional and/or epigenetic
changes that promote synergism for gene induction and regu-
lation after subsequent exposure to type I and type II IFNs (Fig.
1). Noticeably, IFN priming involves increased association of
similar or different types of IFN receptors (53). Under this
mechanism, type I IFNs augment IFN signaling via association
of type I and II IFN receptor subunits. Conversely, IFN prim-
ing for IFN signaling occurs but involves only STAT1 and not
STAT2 or STAT3 (61). Priming for production of large
amounts of type I IFNs is mediated by an autoamplification
loop in which IFN induces expression of the transcription
factor IFN regulator factor 7 (Irf7) that activates IFN gene
promoters (61). This step creates a robust priming effect, where
IFN enhances positive signaling by recruiting other Irfs. For
example, the formation of the heterotrimeric transcription fac-
tor complex known as ISGF3 between Stat1 and IFN-regulatory
factor 9 (Irf9) required type I IFN priming and prolonged IFN
activation (Fig. 1A) (62, 63). Those complexes elicited Stat1
regulation over gene promoters with GAS and/or interferon-
stimulated response elements (ISRE) (64) allowing regulation
of genes with either one or both elements such as the IFN-
regulated cytokine CXCL10/Cxcl10 (IP-10) (65). Conse-
quently, IFN priming elicits regulation of complex biological
process via epigenetic remodeling and enrichment of STAT1-
binding motifs in mice (66). For example, microglial reactive
oxygen species production in response to IFNs required
simultaneous modification of three mechanisms, including
up-regulation of the NADPH oxidase subunit NOX2, up-
regulation of NO production, and the reduction of intracel-
lular GSH levels (67).
Recently, it was reported that un-phosphorylated STATs
play roles modulating the IFN signaling response. For example,
un-phosphorylated STAT1 (U-STAT1) is capable of regulating
a set of ISGs that offer some protection against various viruses
but rendered cells resistant to chemotherapy and radiation (68,
69). Studies in mouse models of arthritis and experimental
autoimmune encephalomyelitis (EAE) determined that U-
Stat1 regulated ISGs that are regularly induced later rather than
earlier after stimulation with either IFN or IFN (68). More-
over, evidence suggests that IFN priming involves regulation
of microRNAs, as suppression of miR-3473b limited activation
of primed macrophages (70).
To counterbalance the effect of IFN priming and receptor
activation, cells also activated precise complementary inhibi-
tory mechanisms at different levels (Fig. 1). At the plasma mem-
brane, suppressor of cytokine signaling proteins block receptor
activation by binding to the activated JAK catalytic sites, thus
turning off downstream signals. Moreover, at the cytoplasm, an
increase in un-phosphorylated STAT2 binds pStat1 to diminish
its nuclear translocation during continuous IFN stimulation
possibly eliciting adaptation to long-term IFN stimulation
(71). In the nuclei, protein inhibitors of activated STAT (PIAS)
associate with activated STAT dimers via their zinc-binding
ring finger domain in the center of the molecule, preventing
them from binding to the DNA (72). Thus, a primed innate
immune system modulates the functions of IFNs and defines
the host response to underlying triggers of autoimmune
disorders.
Understanding the role of IFN in ADs with mouse
models
Several mouse models of ADs, such as SLE, RA, collagen-
induced arthritis (CIA), and EAE have proven the essential role
of IFN both in promoting and suppressing different stages
during AD progression. For example, it is known that both
ifng/ and stat1/ mice are highly susceptible to EAE (73,
74). In contrast, it has been shown that MHC-II induced by
IFN-hyperproducing T cells is important on the disease
course of CIA and RA (75). These data suggest that IFN via the
JAK/Stat1 pathway modulates AD progression. However, tar-
geting the function of IFN at different disease stages is essen-
tial to understand its biological role. Indeed, administration of
mouse IFN applied at very early stages of EAE aggravates the
disease because of highly producing IFN CD4 T cells (76).
However, at a later stage, administration of IFN reduces the
severity of EAE when it is mediated by CD4 Th17 cells (76).
Similarly, IFN is required, even in the presence of complete
Freund’s adjuvant, at the onset and development of severe
arthritis following immunization with glucose-6-phosphate
isomerase (77). The described evidence indicates that CIA and
EAE are more Th17 cell-mediated disease models instead of
pure Th1 cell-mediated diseases, where IFN exerts a dynamic
and context-dependent response. Although IFN may be a rea-
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sonable target for clinical trials, the lack of biomarkers defining
when to start or stop intervention limits the therapeutic value
of IFN. Specifically, there is a need for markers that determine
the availability of IFN-producing cells at different time points
during the immune stimulus. These limitations probably
account for the current narrow therapeutic index and inade-
quate clinical utility of IFN (78). As a result, most of the ongo-
ing preclinical development is concentrated on its inducers, in
particular IL-12 or IL-18 (79).
Despite the benefits from mouse models, human ADs are
chronic inflammation processes instead of short-term and self-
limited diseases induced in preclinical models. To address this
issue, our laboratory designed a mouse model carrying deletion
of the ifng 3-untranslated region adenylate uridylate-rich
element (ARE). The persistent serum levels of IFN, due to
increased stability of mRNA, result in gradual establishment of
SLE-like autoimmunity (80). More importantly, we have pro-
vided evidence that heterozygous ARE-del mice share similar
levels of autoantibodies and demonstrate a histological score of
tissue damage in target organs like that seen in homozygous
ARE-del mice that express twice the systemic IFN levels (80,
81). This evidence suggests the existence of a threshold level of
IFN that, when crossed, results in a more severe pathology.
Similarly, in another model of lupus, mutation of ring finger
and CCCH-type domains 1 (rc3h1/roquin) reduced the rate of
decay of IFN mRNA and increased IFN signaling. As a result,
germinal center B cells increased their numbers and production
of autoantibodies (82). Despite the significant overlap between
genes induced by either type I and type 2 IFNs, these models
strongly suggest that chronic exposure to IFN causes or con-
tributes to SLE-like disease. Hence, development of models for
long-term inflammation could be essential for understanding
the differences between disease stages.
IFN-mediated chronic inflammation, checkpoint
inhibitors, and immunotherapy in ADs
Traditionally, “high” serum levels of IFN (referred herein as
IFN levels) are associated with pro-inflammatory active dis-
ease, whereas “low” IFN levels are associated with anti-inflam-
matory inactive autoimmune disease. As levels of IFN are
compared with healthy individuals, there is no consensus of
what “high” and “low” IFN levels mean. Data from pre-clinical
and clinical studies in mice and humans showed administration
of type 1 IFNs (IFN and -) generally exert a linear dose
response, whereas exogenous IFN exhibits a “bell-shaped”
dose-response curve (83). A “bell-shaped” dose response is
characterized by induction of stimulatory effects at low doses
until it reaches a summit point where additional dosing cause
inhibitory activity and deleterious effects (84). These data sug-
gest the function(s) of endogenous and exogenous IFNs are
probably defined by the dynamics between systemic and local
inflammatory environments. In the local environment, stimu-
latory and inhibitory pathways are activated to limit inflamma-
tion and destruction of self-tissues (85). Recent evidence
showed that IFN is the main regulator of programmed cell
death protein 1 (PD-1) and its two ligands, PD-L1 (B7-H1 or
CD274) and PD-L2 (B7-DC or CD273) (86). This fact suggests
that chronic inflammation influences the local co-inhibitory
pathways in autoimmunity. In ADs, PD-1 (CD279) is the most
studied co-inhibitory receptor, although the role of other
checkpoint inhibitors such as cytotoxic T lymphocyte associ-
ated protein 4 (CTLA4, CD152) is more controversial (87).
PD-1 and CTLA4 have critical, multifaceted roles in regulating
the balance among T cell activation, tolerance, and immuno-
mediated tissue damage. Evidence showed that polymorphisms
at the mouse Pdcd1 and Ctla4 promoters have been associated
with susceptibility to develop AD such as in SLE and AR (56).
These facts reminded us that insufficient co-inhibition can also
promote the development and progression of AD.
Immunotherapy targeting checkpoint inhibitors, such as
PD-L1 and CTLA4, is one of the most rapidly growing fields in
cancer therapy. Nevertheless, the issue with checkpoint block-
ade is the occurrence of associated toxicities termed immune-
related adverse events (irAEs). Generally, AD patients are
thought to be at higher risk of developing hematological malig-
nancies such as Hodgkin’s lymphoma or cervical cancer due to
the underlying dysregulation of their immune system and anti-
inflammatory treatment regime (88). Because of this, therapeu-
tic use of check point inhibitors in patients with ADs develop-
ing tumors had mixed results so far. In a small cohort of AD
patients that develop melanoma, CTLA4 blockade induces
tumor growth inhibition, but 25–50% developed mild to mod-
erate exacerbations of their AD or experienced conventional
CTLA4-induced irAEs, respectively (10). Nevertheless, the
high risk of IrAEs makes the use of checkpoint inhibitors con-
troversial even in patients with certain autoimmune diseases
(pernicious anemia, Crohn’s disease, ulcerative colitis, SLE, and
psoriasis) that develop tumors. Therefore, understanding the
regulation, function, and importance of the IFN signaling
detailed in this review could help to unravel new therapeutic
options for ADs and other chronic diseases, including cancer.
Summary
Overall, there is a consensus that the effect of IFN signaling
is largely controlled in a multidimensional fashion where tim-
ing, exposure levels, target organ, and cellular environment
define the outcome of the immune response to IFN expres-
sion. As such, interventions altering the IFN activity will be
approached with great attention and thoughtfulness as to
both local and systemic effects in a wide variety of disease
states. This cautious approach arises because IFN impacts
the balance between protection and development of autoim-
mune responses. Hence, regardless of the activated pathways,
IFN will directly or indirectly determine the dynamics of
inflammation in subjects with underlying autoimmunity. Al-
though this review focused on immune cells and autoimmunity,
these same principles are starting to be extended to define the
role of IFN in other chronic conditions such as cancer and
immunotherapeutic approaches to treat cancer. Specifically,
the functions of IFN are being reexamined to better under-
stand how it is impacting defined pathogenic or controlled out-
comes. Considering IFN priming and cross-regulation as an
existing pre-condition during the different stages of autoim-
mune diseases or in certain types of cancers will help to develop
a better understanding of the role of this important immuno-
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regulatory molecule in disease initiation, progression, and
treatment.
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